SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MGNX -- MacroGenics
An SI Board Since November 2013
Posts SubjectMarks Bans Symbol
188 21 0 MGNX
Emcee:  scaram(o)uche Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
88Great, at least they may not follow HALO (or PBYI) steps/path!Miljenko Zuanic-1/23/2018
87Gets past futility analysis, SOPHIA trial.scaram(o)uche-1/23/2018
86Thanks, didn't know about presentation. Looks like it may live on, subset oscaram(o)uche-1/18/2018
85files.shareholder.com <Phase 1b/2 Study of Margetuximab Plus Pembrolizumab iMiljenko Zuanic-1/18/2018
84K-224 preliminary results in abstract: abstracts.asco.org On many occasion (HMiljenko Zuanic-1/16/2018
83Presentation wassssss....zzzzzzzzzMiljenko Zuanic11/11/2018
82MGNX flat for last 12 months. Can S. Koeing bring some light at JPM18 (4w schedMiljenko Zuanic-1/11/2018
81ir.macrogenics.com Are Genentech R&D machineries slowing down? Maybe MGNXMiljenko Zuanic-1/4/2018
80Thanks, Miljenko (eom).DewDiligence_on_SI-1/2/2018
79Well, at this point we know Opdivo/Keytruda activity (limited, but small improveMiljenko Zuanic-1/2/2018
78Outcome of this trial will set stage for ALL new PD-1 inhibitors/candidates. PleDewDiligence_on_SI-1/2/2018
77seekingalpha.com Outcome of this trial will set stage for ALL new PD-1 inhibitorMiljenko Zuanic-1/2/2018
76OT TRIL call: thx, but not yet to a level where put sales are interesting. Watctuck-11/9/2017
75nice call! (not enjoying it at all! ;-)scaram(o)uche-11/9/2017
74Thanks!scaram(o)uche-11/8/2017
73<I am interested in knowing if 012 contributed the variable region to MGD013.Miljenko Zuanic111/8/2017
72We were all surprised by the size of the 012 deal. I'm not going to try to scaram(o)uche-11/7/2017
71>> I could easily see it coming back some. << I could easily see a scaram(o)uche-11/7/2017
70>> saying folks who sold a few weeks ago are now chasing TRIL stock into bscaram(o)uche-11/7/2017
69Partially OT >>Have you considered that seller's remorse could be extuck-11/7/2017
68>> SITC in general seems be getting regarded as something of a bust, wrt tscaram(o)uche-11/7/2017
67MGA012 at SITC (so far, just the dose escalation phase data): >>A phase tuck-11/7/2017
66Two months in, I'm just pleased that the first patients dosed (a presumptionscaram(o)uche-10/25/2017
65So, Incyte does not believe in PD-1 x LAG-3 bispecific? Why not sub-license,....Miljenko Zuanic-10/25/2017
64Incyte puts big cash upfront for anti-PD1 MGA012, with MGNX retaining combo righscaram(o)uche-10/25/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News